Delineate GTM brain

Delineate builds AI-powered research datasets for pharmaceutical scientists designing clinical trials and making development decisions.

category

Clinical evidence synthesis

market profile

  • text: Clinical development teams spend substantial time converting published trials and charts into structured evidence for analysis.
  • text: The company reports partnerships with two top-10 pharmaceutical companies on systematic reviews.

personas

  • title: Head of clinical pharmacology
    pains:
    • Dose and trial design decisions depend on fragmented prior evidence.
    • Manual extraction delays modeling and scenario analysis.
  • title: Pharmacometrics or model-informed drug development lead
    pains:
    • Published curves and safety data require laborious digitization and verification.
    • Needs consistent, analysis-ready inputs for model-based meta-analysis.
  • title: Clinical development program lead
    pains:
    • Trial design delays extend expensive development timelines.
    • Needs evidence traceability and confidence before using automated extraction in decisions.

icp

  • text: Large pharmaceutical companies with active clinical development portfolios and dedicated quantitative science teams.
  • text: Biopharma organizations conducting evidence-heavy competitive benchmarking or model-informed drug development.

message pillars

  • text: Build quantitative evidence for consequential development decisions.
  • text: Supply quantitative evidence to research teams.
  • text: Support consequential decisions with evidence.

objections

  • objection: Can AI extraction be trusted for high-stakes research?
    response: Evaluate a sample against expert extraction, including provenance, quality control and error rates.
  • objection: Will the dataset work in our modeling workflow?
    response: Agree on schema, endpoints and a representative export before a larger project.
  • objection: Why not use our existing internal review team?
    response: Compare time to an analysis-ready dataset and scientist review effort on a shared evidence set.

competitors

  • name: Trials.ai
    why: Applies prior trial evidence to protocol design and optimization.
  • name: Medidata
    why: Provides clinical trial design and planning tools for pharmaceutical sponsors.
  • name: Phesi
    why: Offers data-driven trial design and planning capabilities.

influencers

  • name: Emily Nieves
    why: Delineate co-founder and CEO who speaks about AI for trial design.

keywords

  • clinical trial evidence synthesis
  • pharmacometrics data extraction
  • model based meta analysis datasets
  • clinical trial design AI
  • published survival curve digitization
  • drug development competitive intelligence

voice

  • Scientific
  • Evidence-led
  • Decision-focused

signals

  • text: A sponsor is planning a new trial phase or protocol and needs a synthesis of historical studies.
  • text: A clinical pharmacology team is building an MBMA or benchmarking dataset from many publications.

stack

  • NONMEM

pricing

model: unknown

motion

sales_led

channels

  • LinkedIn
  • industry events

confidence

medium

Founders

  • name: Emily Nieves
    title: Founder/CEO
    role: CEO
    bio: Co-founder at Delineate. Previously she was an MIT PhD Candidate in Biological Engineering and worked at Pfizer and AstraZeneca where she focused on applying AI to modeling and simulation for drug development optimization.
  • name: Jawad Iqbal
    title: Founder/CTO
    role: CTO
    bio: Co-Founder and CTO of Delineate. Masters thesis in Robotics/AI with 2 research publications. Former technical project manager for high impact digital transformation projects within Skunkworks (Advanced Development) division at Lockheed Martin.

Back to YC companies